Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma multiforme is an aggressive brain tumor with complex genetic alterations.
• Cyclin-dependent kinase (CDK) inhibitors, such as p15 (encoded by MTS2) and p16 (encoded by MTS1), play crucial roles in cell cycle regulation.
• Understanding the genetic status and functional impact of these inhibitors is vital for glioblastoma research.

Purpose of the Study:

• To investigate the genetic alterations of the MTS2 gene in glioblastoma.
• To assess the functional role of MTS2 (p15) and MTS1 (p16) in glioblastoma cell proliferation.
• To determine the primary mechanism of MTS1 and MTS2 inactivation in glioblastomas.

Main Methods:

• Semi-quantitative PCR was used to detect deletions in the MTS2 gene in 32 glioblastoma samples.
• Single-strand conformation polymorphism (SSCP) analysis was performed to identify mutations.
• MTS2 and MTS1 genes were expressed in U-87 human glioblastoma cells to evaluate their functional effects on proliferation.

Main Results:

• Evidence of homozygous and hemizygous deletions of MTS2 was found in 14 out of 32 glioblastomas.
• No mutations in MTS2 were detected, although one polymorphism was identified.
• Expression of MTS2 and MTS1 significantly inhibited U-87 cell proliferation, but this effect diminished over time.

Conclusions:

• The MTS2 gene (p15) functions as a tumor suppressor in glioblastoma.
• Homozygous deletions are the predominant mechanism for the inactivation of MTS1 and MTS2 in glioblastomas.
• Further research into CDK inhibitors may offer therapeutic strategies for glioblastoma.